NICE Enables Access to First Treatment That Targets the Underlying Pathophysiology of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1

Contributed by: Business Wire

Logo

Tags

Pharmaceutical

Health

Other Health

CRYSVITA

More Like This

Kyowa Kirin Responds to NICE’s Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1

Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphataemia (XLH)

Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

PR Newswire associated0

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

PATIENTS ACROSS ENGLAND AND WALES GAIN ACCESS TO NEW TREATMENT OPTION FOR MANTLE CELL LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING POSITIVE NICE DECISIONS